河北医学2018，Vol.24Issue(6)：905-908,912-914,7.DOI:10.3969/j.issn.1006-6233.2018.06.007
莫西沙星联合舒利迭吸入对慢性阻塞性肺疾病急性加重期患者血清SAA TGF-β1 copeptin sICAM-1的影响
Effects of Moxifloxacin Combined Seretide on Serum SAA TGF-β1 Copeptin, and sICAM-1 of AEC OPD
摘要
Abstract
Objective: To study the clinical efficacy of moxifloxacin combined seretide inhalation in a-cute exacerbation of chronic obstructive pulmonary disease ( AECOPD) , and its effects on serum amyloid A (SAA), transforming growth factor-β1 (TGF -β1), copeptin, soluble intercellular adhesion factor-1 (sI-CAM-1) . Methods: A total of 102 AECOPD patients were enrolled of our hospital from December 2015 to December 2016. They were randomly divided into control group and experimental group ( n ＝ 51) . The control group was treated with seretide combined Amoxicillin -clavulanic acid inhalation on the basis of routine treat-ment. The experimental group was treated with moxifloxacin combined seretide inhalation. To compare the changes of serum SAA, TGF-β1, copeptin and sICAM-1 in two groups, to observe the changes of serum CO2A (PaCO2) and oxygen partial pressure (PaO2), and to detect lung function: (FEV1), vital capacity ( FVC) and FEV1 / FVC were used to assess the quality of life and dyspnea of patients with COPD: Medical Research Council Dyspnoea Scale( mMRC) , COPD Assessment Test( CAT) , and adverse events. Results:After treatment, the effective rate (92.16%) in the experimental group was significantly higher than that in the control group ( P ＜0.05) . FEV1, FCV, FEV1 / FCV were improved after treatment, the difference was statis-tically significant ( P ＜0.05) , and the experimental group improved more than the control group ( P ＜0.05) . Compared with the control group, the difference was statistically significant ( P ＜0.05) . The PaO2 of the two groups was significantly higher than that of the control group (P ＜0.05)., and the experimental group was sig-nificantly lower than the control group ( P ＜0.05) , the difference was statistically significant ( P ＜0.05) , and the difference was statistically significant (P ＜0.05). There was no significant difference between the two groups ( P＞ 0.05) . Conclusion: The clinical efficacy of moxifloxacin combined seretide inhalation on AECO-PD patients can reduce serum SAA, TGF-β1, copeptin, sICAM-1 levels, improve arterial oxygen pressure, quality of life and lung function.关键词
慢性阻塞性肺疾病/急性加重期/莫西沙星/舒利迭Key words
Chronic obstructive pulmonary disease/Acute exacerbation/Moxifloxacin/Seretide引用本文复制引用
于晴,王靖賾..莫西沙星联合舒利迭吸入对慢性阻塞性肺疾病急性加重期患者血清SAA TGF-β1 copeptin sICAM-1的影响[J].河北医学,2018,24(6):905-908,912-914,7.基金项目
内蒙古自然科学基金项目,(编号:2013MS1116) （编号:2013MS1116）
